# Real-world Efficacy and Safety of Neoadjuvant Dostarlimab in Patients With dMMR/MSI-H Locally Advanced Rectal Cancer

> **NCT07269249** · — · RECRUITING · sponsor: **National Cancer Institute, Naples** · enrollment: 50 (estimated)

## Conditions studied

- Locally Advanced Rectal Cancer (LARC)

## Interventions

- **DRUG:** Dostarlimab

## Key facts

- **NCT ID:** NCT07269249
- **Lead sponsor:** National Cancer Institute, Naples
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2027-01
- **Final completion:** 2027-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07269249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07269249, "Real-world Efficacy and Safety of Neoadjuvant Dostarlimab in Patients With dMMR/MSI-H Locally Advanced Rectal Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07269249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*